thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-20. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
==== Dosage ==== Colistin sulfate and colistimethate sodium may both be given intravenously, but the dosing is complicated. The different labeling of the parenteral products of colistin methanesulfonate in different parts of the world was noted by Li et al. Colistimethate sodium manufactured by Xellia (Colomycin injection) is prescribed in international units, whereas colistimethate sodium manufactured by Parkdale Pharmaceuticals (Coly-Mycin M Parenteral) is prescribed in milligrams of colistin base:
== Synthesis == In the synthesis of melanotan II, an ε-amino group of lysine and an γ-carboxy group of aspartic acid have their orthogonal protection removed before undergoing a carbodiimide mediated lactamization, leading to an intermediate. This intermediate, when attached to N-acetylnorleucine, forms melanotan II. The entire process can be accomplished in 12 steps with an overall yield of 2.6%, and the product is more than 90% pure without preparative chromatography.
=== OXGR1 receptor-dependent bioactions === OXGR1 (also known as GPR99) is a G protein-coupled receptor, i.e., a receptor located on the surface membrane of cells that binds certain ligands and is thereby stimulated to activate G proteins that elicit pre-programmed responses in their parent cells. OXGR1 was identified as a receptor for: a) α-ketoglutarate in 2004; b) three leukotrienes viz., leukotrienes E4, C4, and D4 in 2013. and c) itaconate in 2023. These ligands have the following relative potencies in stimulating responses in OXGR1-bearing cells (Note that LTE4 can stimulate OXGR1 at concentrations far lower than those of the other four ligands):
1993/3045) Broadcasting (Prescribed Countries) (Amendment) Order 1993 (S.I. 1993/3046) Broadcasting (Foreign Satellite Programmes) (Specified Countries) (Amendment) Order 1993 (S.I. 1993/3047) Road Vehicles (Construction and Use) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3048) Public Lending Right Scheme 1982 (Commencement of Variation) Order 1993 (S.I. 1993/3049) Notification of New Substances Regulations 1993 (S.I. 1993/3050) Hearing Aid Council Monetary Penalty (Increase) Order 1993 (S.I. 1993/3052) Commercial Agents (Council Directive) Regulations 1993 (S.I. 1993/3053) Local Authorities (Capital Finance) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3054) Income Tax (Interest Relief) (Qualifying Lenders) (No. 4) Order 1993 (S.I. 1993/3055) Education (University Commissioners) Order 1993 (S.I. 1993/3056) National Health Service Trusts (Consultation on Dissolution) (Scotland) Regulations 1993 (S.I. 1993/3057) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) (Partial Revocation No.2) Order 1993 (S.I. 1993/3058) Non-Domestic Rating Contributions (Scotland) Amendment Regulations 1993 (S.I. 1993/3059) New Town (Livingston) Winding Up Order 1993 (S.I. 1993/3060) New Town (Irvine) Winding Up Order 1993 (S.I. 1993/3061) New Town (Cumbernauld) Winding Up Order 1993 (S.I. 1993/3062) Herring (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3063) Passenger and Goods Vehicles (Recording Equipment) (Approval of Fitters and Workshops) (Fees) (Amendment) Regulations 1993 (S.I.
Sources: en.wikipedia.org
== Structure == Similar to G protein-coupled receptors (GPCRs), AdipoR1 also possesses 7 transmembrane domains. However, AdipoR1 is orientated oppositely to GPCRs in the membrane (i.e., cytoplasmic N-terminus, extracellular C-terminus) and does not associate with G proteins.
Some of the most striking advances in early anatomy and physiology took place in Hellenistic Alexandria. Two of the most famous anatomists and physiologists of the third century BC were Herophilus and Erasistratus. These two physicians helped pioneer human dissection for medical research, using the cadavers of condemned criminals, which was considered taboo until the Renaissance—Herophilus was recognized as the first person to perform systematic dissections. Herophilus became known for his anatomical works, making impressive contributions to many branches of anatomy and many other aspects of medicine. Some of the works included classifying the system of the pulse, the discovery that human arteries had thicker walls than veins, and that the atria were parts of the heart. Herophilus's knowledge of the human body has provided vital input towards understanding the brain, eye, liver, reproductive organs, and nervous system and characterizing the course of the disease. Erasistratus accurately described the structure of the brain, including the cavities and membranes, and made a distinction between its cerebrum and cerebellum.During his study in Alexandria, Erasistratus was particularly concerned with studies of the circulatory and nervous systems. He could distinguish the human body's sensory and motor nerves and believed air entered the lungs and heart, which was then carried throughout the body. His distinction between the arteries and veins—the arteries carrying the air through the body, while the veins carry the blood from the heart was a great anatomical discovery.
== Types of diabetes mellitus == Prediabetes – Main types of diabetes: Type 1 diabetes – disease that results in autoimmune destruction of insulin-producing beta cells of the pancreas. Type 2 diabetes – metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. Disease of affluence – type 2 diabetes is one of the "diseases of affluence", which include mostly chronic non-communicable diseases for which personal lifestyles and societal conditions associated with economic development are believed to be important risk factors. Gestational diabetes – Gestational diabetes, is a temporary condition that is first diagnosed during pregnancy. Like type 1 and type 2 diabetes, gestational diabetes causes blood sugar levels to become too high. It involves an increased risk of developing diabetes for both mother and child. During pregnancy, the body becomes resistant to insulin, so that more glucose feeds the fetus. Unlike other types of diabetes, gestational diabetes is not a permanent disease, but disappears on its own with the birth of the child. However, this condition that appeared during the 9 months of pregnancy predisposes the woman to long-term diabetes. Other types of diabetes: Congenital diabetes – Cystic fibrosis-related diabetes – Steroid diabetes – Monogenic diabetes –
Sources: en.wikipedia.org
Broadly, aptamers are small molecules composed of either single-stranded DNA or RNA and are typically 20-100 nucleotides in length, or ~3-60 kDa. Because of their single-stranded nature, aptamers are capable of forming many secondary structures, including pseudoknots, stem loops, and bulges, through intra-strand base pairing interactions. The combinations of secondary structures present in an aptamer confer it a particular tertiary structure which in turn dictates the specific target the aptamer will selectively bind to. Because of the selective binding ability of aptamers, they are considered a promising biomolecule for use in pharmaceuticals. Additionally, aptamers exhibit tight binding to targets, with dissociation constants often in the pM to nM range. Besides their strong binding ability, aptamers are also valued because they can be used on targets that are not capable of being bound by small peptides generated by phage display or by antibodies, and they are able to differentiate between conformational isomers and amino acid substitutions. Also, because aptamers are nucleic-acid based, they can be directly synthesized, eliminating the need for cell-based expression and extraction as is the case in antibody production. RNA aptamers in particular are capable of producing a myriad of different structures, leading to speculations that they are more discriminating in their target affinity compared to DNA aptamers.
== Plot summary == Anathem is set on the fictional planet of Arbre. Thousands of years before the events in the novel, the planet's intellectuals entered concents (monastic communities) to protect their activities from the collapse of society. The avout (intellectuals separated from Sæcular society) are banned from possessing or operating most advanced technology and are supervised by the Inquisition, which answers to the outside world. The avout are normally allowed to communicate with people outside the walls of the concent only once every year, decade, century, or millennium, depending on the particular vows they have taken. The narrator and protagonist, Fraa Erasmas, is an avout at the Concent of Saunt Edhar. His teacher, Fraa Orolo, discovers that an alien spacecraft is orbiting Arbre – a fact that the world government (Sæcular Power) attempts to cover up. Erasmas becomes aware of Orolo's discovery after Orolo is banished (in a rite called Anathem) from the concent for using a video camera (a forbidden technology) to observe the ship. The presence of the alien ship soon becomes an open secret among many of the avout at Saunt Edhar. The alien ship eventually declares its presence by shining a laser upon several Millenarian Maths (the bastions of those avout who have taken a thousand-year vow of isolation). Shortly after that, the Sæcular Power summons many avout from Saunt Edhar, including Erasmas and a Millenarian named Fraa Jad. The avout are told to travel to the concent of Saunt Tredegarh to attend a Convox (a joint conference of the avout and the Sæcular Power).
July 13, 1983: Law on the rights and obligations of civil servants. July 13, 1983: Law amending the Labor Code and the Penal Code concerning professional equality between women and men (Roudy Law): gender equality in the workplace. January 4, 1984: Law amending the Labor Code concerning parental education leave and part-time work for parents of young children. February 29, 1984: Decree creating, under the Minister Delegate to the Prime Minister for Women's Rights, a terminology commission responsible for studying the feminization of titles and functions, and more generally, vocabulary concerning women's activities. May 7, 1984: Law on acquiring French nationality through marriage. July 12, 1984: Bill concerning alimony. December 4, 1984: Decree on work permits issued to foreign workers. December 22, 1984: Law on the intervention of family benefits agencies for recovering unpaid alimony. January 4, 1985: Law on measures in favor of young families and large families. May 31, 1985: Decree on the responsibilities of the Minister for Women's Rights; this results in the ministry's autonomy. December 23, 1985: Law establishing equality between spouses in matrimonial regimes and between parents in managing the property of their minor children. January 6, 1986: Law adapting health and social legislation to the transfer of responsibilities in social and health assistance. March 11, 1986: Circular on the feminization of job titles, roles, ranks, or honors. May 2, 1986: Decree concerning the Delegate for Women's Affairs. December 29, 1986: Law relating to the family.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.